Rafferty Asset Management
MBX

Rafferty Asset Management’s MBX Biosciences MBX Stock Holding History

Rafferty Asset Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Buy
+6,410
New +$224K ﹤0.01% 980
2026
Q1 		– Sell
-8,113
Closed -$256K – 1153
2025
Q4 		$256K Buy
+8,113
New +$197K ﹤0.01% 1027

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Rafferty Asset Management's MBX Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in MBX Biosciences (MBX) in Q2 2026: 6,410 shares worth $354K. The stake represents ﹤0.01% of the portfolio and ranks #980 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in MBX as recently as Q4 2025.

Rafferty Asset Management first reported a position in MBX in Q4 2025 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Rafferty Asset Management held 6,410 shares of MBX Biosciences worth $354K as of Q2 2026.
  • MBX Biosciences was a new Rafferty Asset Management position in Q2 2026.
  • MBX Biosciences made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #980 holding.
  • Rafferty Asset Management first reported a position in MBX Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.